Defining the economic burden and the pathophysiology of type 2 inflammation in asthma.
A discussion on the diagnostic process and the biomarkers commonly tested in asthma.
There are clear differences between the biologics approved to treat asthma, and finding the right one for a patient requires shared decision-making conversations.
November 28th 2020, 1:45pm
As the only biologic on the market, dupilumab has replaced most of the more traditional treatments for atopic dermatitis, said David Pariser, MD, senior physician at Pariser Dermatology Specialists.
November 25th 2020, 2:45pm
Patients with asthma can improve their disease control and sleep quality, while reducing depression and anxiety through a behavior change intervention aimed at increasing their physical activity.
November 17th 2020, 2:15pm
Expansion of insurance coverage due to the Affordable Care Act led to a reduction in the use of emergency services for patients with asthma in New York City.
November 15th 2020, 2:30pm
Dupilumab, with or without topical corticosteroids, significantly reduced pain and discomfort in patients with moderate to severe atopic dermatitis.
November 11th 2020, 3:00pm
Treatment targets include several interleukins, immunoglobulin E, and alarmins, pointed out Nicola Hanania, MD, MS, pulmonary critical care physician and director, Airway Clinical Research Center, Baylor College of Medicine, Houston.
November 8th 2020, 4:00pm
Overuse of reliever inhalers among adult patients with asthma is prevalent, but does not necessarily translate into higher all-cause health care utilization (HCU), according to a study published in Scientific Reports.
November 7th 2020, 3:30pm
Categorizing by eosinophilic/noneosinophilic subtype enables better targeted treatment, noted Anne Reihman, MD, third-year pulmonary and critical care fellow, University of Colorado, Division of Pulmonary Sciences and Critical Care Medicine.
November 6th 2020, 2:30pm
Vitamin D used as an adjuvant therapy in children with severe atopic dermatitis may improve clinical outcomes, according to a recent study.
October 31st 2020, 12:30pm
Despite the price, adherence to biologics for asthma is usually good because of the effectiveness, said J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.
October 28th 2020, 7:30pm
When the first biologic to treat asthma was approved by the FDA in 2003, it needed to be administered subcutaneously in the physician’s office. Now, there are 3 options available for at-home use: mepolizumab, benralizumab, and dupilumab.
